Tag: Gensight
GenSight Biologics wants to extend its visibility beyond April 2024 – 04/05/2024 at 10:31
(AOF) – GenSight Biologics (-5.89% to 0.39 euros) announces that its cash position stands at 2.2 million euros as of March 31, 2024, compared to 2.1 million euros as of…
GenSight: financial visibility guaranteed until the end of April – 04/05/2024 at 12:33
(CercleFinance.com) – GenSight Biologics fell on Friday on the Paris Stock Exchange, with analysts noting the continued lack of visibility over the company’s cash flow. As of March 31, its…
GenSight Biologics wants to extend its visibility beyond April 2024
(AOF) – GenSight Biologics (-5.89% to 0.39 euros) announces that its cash position stands at 2.2 million euros as of March 31, 2024, compared to 2.1 million euros as of…
GenSight: the stock falls, financial visibility limited – 03/25/2024 at 10:41
(CercleFinance.com) – GenSight Biologics fell sharply on Monday on the Paris Stock Exchange after reporting annual results marked by a lack of financial visibility. The biopharmaceutical company, specializing in gene…
Gensight Biologics reduces its losses in 2023 – 03/22/2024 at 6:25 p.m.
(AOF) – Gensight Biologics posts an operating loss of 29.7 million euros in 2023 compared to 27.8 million euros in 2022. This increase of 1.9 million euros is mainly linked…
Gensight Biologics cuts losses in 2023
(AOF) – Gensight Biologics posts an operating loss of 29.7 million euros in 2023 compared to 27.8 million euros in 2022. This increase of 1.9 million euros is mainly linked…
GenSight Biologics: new data on Lumevoq presented this week
(AOF) – GenSight Biologics today announced that new data and scientific analyzes relating to the Lumevoq gene therapy will be presented at the 50th Annual Meeting of the North American…
Gensight Biologics SA: The Goldman Sachs Group, Inc. crosses the threshold of 5% of capital
LR source AMF Published on 02/16/2024 at 10:00 a.m. Photo credit © Euronext (Boursier.com) — The company The Goldman…
GenSight: Goldman Sachs exceeds 5%
(CercleFinance.com) – Goldman Sachs Group declared to the AMF that, on February 13, it had exceeded the thresholds of 5% of the capital and voting rights of GenSight Biologics and…
GenSight Biologics: shareholders hand over 5 ME
By Arnaud Bivès Published on 02/08/2024 at 08:53 a.m. (Boursier.com) — GenSight whose cash flow situation was particularly tense, has just completed…
GenSight Biologics: Laurence Rodriguez succeeds Bernard Gilly
By Alexandra Saintpierre Published on 01/16/2024 at 7:38 p.m. Photo credit © NissierPictures (Boursier.com) — The Board of…
Gensight Biologics: visibility until mid-February 2024 – 12/27/2023 at 09:43
(AOF) – Gensight Biologics announces that its cash flow horizon has been extended from mid-January to mid-February 2024. The biotech specializing in innovative gene therapies for retinal neurodegenerative diseases and…